Virus therapy takes on tough colorectal cancer in new trial

NCT ID NCT07446322

Recruiting now Disease control Sponsor: Oncolytics Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a virus-based drug (pelareorep) to standard chemotherapy can help people with a specific type of advanced colorectal cancer that has stopped responding to initial treatment. About 60 adults whose cancer has spread and has certain genetic features (RAS mutation, MSS) will be randomly assigned to receive either standard chemo plus the virus or standard chemo alone. The goal is to see if the combination shrinks tumors better and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma renal cell adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRC MSS METASTATIC COLORECTAL CANCER RAS-MUTATED METASTATIC COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Central Alabama Research
RECRUITING

Homewood, Alabama, 35209, United States
Gabrail Cancer Center
RECRUITING

Canton, Ohio, 44718, United States
Summit Health Cancer Center
RECRUITING

Florham Park, New Jersey, 07932, United States